Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$32.43 +0.74%

+$0.18 today

Market cap
$1.77B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 1.00M

Average 0.84M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$142.90M

FY 2025 · Annual

Net Income

-$131.12M

FY 2025 · Annual

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00167.5M0
Cost of Revenue0002.4M
Gross Profit00167.5M(2.4M)
Gross Margin——100.0%—
Research & Development88.19M73.95M83.5M108.45M
Selling, General & Admin22.83M24.61M26.42M34.45M
Operating Expenses111.03M98.55M109.91M140.5M
Depreciation & Amortization3.82M4.09M3.3M2.4M
EBITDA(111.12M)(96.33M)56.7M(128.72M)
EBITDA Margin——33.9%—
Operating Income(111.03M)(98.55M)57.59M(142.9M)
Operating Margin——34.4%—
Interest Income2.03M1.97M4.65M11.78M
Interest Expense0000
Other Income / Expenses(3.91M)(1.86M)(4.18M)11.78M
Income Before Tax(114.94M)(100.42M)53.4M(131.12M)
Pre-Tax Margin——31.9%—
Income Tax Expense001.17M0
Net Income(114.94M)(100.42M)52.23M(131.12M)
Net Margin——31.2%—
EPS (Basic)(2.63)(2.29)0.08(3.05)
EPS (Diluted)(2.63)(2.29)0.08(3.05)
Weighted Avg Shares43.78M43.78M43.8M42.98M
Weighted Avg Shares (Diluted)43.78M43.78M43.8M42.98M

MAZE Earnings Waterfall · TTM

NASDAQ:MAZE · Revenue to Net Income

Key Ratios

EPS$-2.75
Gross Margin24.4%
Net Margin-30.3%
P/E Ratio-10.8
P/S Ratio20.1

Analysis

$20.0M of revenue converted into -$122.5M of net income for the selected period. Gross margin is 24.4% and net margin is -30.3%, showing how much revenue survives after costs and taxes. EPS is $-2.75, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 9, 2026
10-QQuarterly reportNov 9, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
8-KCurrent reportOct 16, 2026

How much revenue does MAZE generate?

Maze Therapeutics, Inc. (MAZE) reported $0.00 of revenue in fiscal 2025.

Is MAZE profitable?

Maze Therapeutics, Inc. (MAZE) reported -$131.12M of net income.